9月21-23日，由中国医药创新促进会（以下简称“中国药促会”）会同中国医疗器械行业协会、中国医院协会、香港交易所、蓝迪国际智库共同主办的第四届医药创新与投资大会（以下简称“大会”）在苏州工业园区隆重召开。
大会作为国内行业瞩目并具有广泛国际影响力的医药创新与投资界盛会，在成功举办前三届大会的基础上，继续坚持“推动国内外社会资本与医药创新结合，提高我国医药产业创新能力”的宗旨，深入解读中国医药创新和投融资政策，充分展示国内外医药创新成果和投资最新动向，为国内外医药创新项目、企业、投资人和资本搭建更加广泛、权威、多元的高端合作交流平台，同时也为业界领袖、专家学者、媒体朋友提供畅所欲言，深度交流的机会。
中国医学科学院、南方医药经济研究所、苏州工业园区、中关村股权投资协会、深圳市坪山区人民政府、美国癌症研究基金会、香港生物医药创新协会、台湾生技医疗产业策进会、日本制药工业协会、BioCentury、中国外商投资企业协会药品研制和开发行业委员会等组织机构与摩根大通（J.P. Morgan）等也给予大会鼎力支持。国家医药监管有关部门领导、国内外院士、全球金融市场四大证券交易平台——香港、纳斯达克、伦敦和上海证券交易所重量级嘉宾，以及国内外医药投资界专家、嘉宾出席了大会。
徐诺药业董事长徐英霖先生在上市公司专场做路演
徐诺药业董事长徐英霖先生受邀参加此次的医药创新与投资大会，并于上市公司专场分享了徐诺药业最新的进展与展望。一方面，徐诺药业努力拓展临床研究和药物研发，打造更全面的产品管线，另一方面，徐诺药业正在为商业化做准备，打造完整的产业价值链，希望有朝一日成长为在国际舞台有影响力的生物制药公司，带动中国制药产业走向全球。
徐诺药业董事长徐英霖先生与投资人一对一交流
关于徐诺药业
徐诺药业是一家专注于肿瘤药物开发的生物制药公司。
徐诺药业目前的产品管线主要包括三款候选药物，艾贝司他、 XP-105 和 XP-102。公司拥有这些药物的全球独家开发、生产和商业化权益。其领先的候选药物艾贝司他正在进行治疗肾细胞癌（与培唑帕尼联用）和单药治疗非霍奇金淋巴瘤的全球关键临床试验。徐诺药业另外一款临床阶段候选药物为可进入临床2期的XP-105（BI 860585），这是一个ATP竞争性的mTORC1 / 2抑制剂，对多种实体瘤有效。徐诺药业的临床前候选药物XP-102（BI 882370）是一个泛-RAF抑制剂。
投资者关系、媒体和商务拓展请联系：
angela.feng@
Use of
Forward-Looking Statements
This press release contains “forward-looking” statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
Xynomic has based these forward-looking statements largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related Xynomic’s financial position and need for additional capital to complete the planned trials and support its continuing operation, risks related to uncertainty in maintaining and obtaining regulatory approval and ultimately commercialize its drug candidates or delays in doing so; and the risks more fully described in Xynomic’s filings thatXynomic may make with theSECin the future. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
